Hot Topics and Issues in the Biosimilars Space: Part Two

Event Date
  • 2/1/2018   6:00 PM - 8:00 PM
    Please arrive early for registration
  • Axinn
    114 West 47th Street
    New York, New York 10036

On-Line Registration (please select one of the following)

Description Amount
Member $20.00 Register
fee ends 1/27/2018
Description Amount
Non-Member $55.00 Register
fee ends 1/27/2018

As the eighth anniversary of the BPCIA approaches, developments in the biosimilars space have seized national attention.  The Supreme Court has interpreted the “patent dance” and “notice of commercial marketing” provisions of the BPCIA in Sandoz Inc. v. Amgen Inc., and the FDA has currently approved nine biosimilar drug products.  In this second installment of the February 2016 program, the panel will discuss recent case law and updates in FDA implementation and policy development.  Strategies for clearing intellectual property hurdles involving biologics in inter partes reviews and the mechanics of the patent dance will also be addressed.

Please join us for an active and engaging discussion of the future of biosimilars.

Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP 
Brian MurphyPartner, Haug Partners LLP
Christine Simmon, Senior Vice President, Policy & Strategic Alliances Executive Director, Biosimilars Council, Association for Accessible Medicines

Moderator: Michael Johnson, Partner, Willkie Farr & Gallagher LLP

Program Schedule
6:00 p.m. – 6:30 p.m. Registration & Pre-reception
6:30 p.m. – 8:00 p.m. Presentation 
8:00 p.m. – 8:30 p.m. Post-reception

Sponsored by